| Document Date: 2013-10-18 16:38:58
Open Document File Size: 731,83 KBShare Result on Facebook
City Gadolinium / Reference / / Company Bayer HealthCare Pharmaceuticals Inc. / / Event FDA Phase / Product Issues / / IndustryTerm diagnostic magnetic resonance imaging / physiological saline solution / yellow solution / contrast media / rubber stopper / chemical / imaging / / MedicalCondition Nephrogenic Systemic Fibrosis Gadolinium-based contrast agents / loss of consciousness / chronic / severe kidney disease / local irritation / hypertension / severe kidney disease / bronchospasm / bronchial asthma / chest pain / laryngeal edema / disease / flushing / headache / kidney disease / moderate irritation / dysgeusia / shock / Carcinogenesis / Acute kidney injury / dysfunction / Chronic / convulsion / nausea / diabetes / allergic disorders / hyperhidrosis / chronic hypertension / conjunctivitis / severe hypersensitivity / injury / diabetes mellitus / urticaria / angioedema / tachycardia / Hypersensitivity / anaphylactic reactions / inflammatory cells / infection / Cardiac arrest / cough / Anaphylactoid/anaphylactic reactions / Pruritus / NEPHROGENIC SYSTEMIC FIBROSIS / chronic renal impairment / fibrosis / hypotension / / MedicalTreatment catheter / resuscitation / hemodialysis / cannula / drug therapy / surgery / dialysis / / Organization Before Gadavist administration / National Science Foundation / DOSAGE AND ADMINISTRATION / FDA / Gadavist administration / / / Position General / / Product Gadavist injection / VOLUME OF GADAVIST INJECTION / Palm Pre Plus Smartphone / elimination / L / / Technology Pharmacokinetics / MRI system / magnetic resonance imaging / Pharmacodynamics / MRI / dialysis / / URL www.fda.gov/medwatch / /
SocialTag |
The recommended dose of Gadavist is 0.1 mL/kg body weight (0.1 mmol/kg), administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second. Flush the intravenous cannula with physiological saline